CRLX101 (formerly IT-101)-A novel nanopharmaceutical of camptothecin in clinical development

Current Bioactive Compounds

Volumn 7, Issue 1, 2011, Pages 8-14

  Young, Cissy ^a   Schluep, Thomas ^b   Hwang, Jungyeon ^a   Eliasof, Scott ^a  

^a Cerulean Pharma Inc   (United States)

^b Independent consultant to Cerulean Pharma Inc   (United States)

Author keywords

Camptothecin; Nanopharmaceutical; Oncology; Topoisomerase 1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CRLX 101; CYCLODEXTRIN; DRUG CARRIER; GEMCITABINE; IRINOTECAN; IT 101; MACROGOL; NANOPARTICLE; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; COLORECTAL CANCER; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; MAXIMUM TOLERATED DOSE; NANOPHARMACEUTICS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

EID: 79953839433     PISSN: 15734072     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340711795163866     Document Type: Article

References (25)

1. Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.-D., Woodle, M.C., Lasic, D.D., Redemann C., Martin, F.J. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic effect. Proc. Natl. Acad. Sci. USA, 1991, 88, 11460-11464.
2. Davis, M.E., Chen Z.G., Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7, 771-782.
3. Matsumura, Y., Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46, 6387-6392.
4. Huang, S.K., Mayhew, E., Gilani, S., Lasic, D.D., Martin, F.J., Papahadjopoulos, D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res., 1992, 52, 6774-6781.
5. Tong, R., Cheng, J. Anticancer polymeric nanomedicines. Polymer Rev., 2007, 47, 345-381.
6. Cheng, J., Khin, K.T., Jensen, G.S., Liu, A., Davis, M.E. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug. Chem., 2003, 14, 1007-1017.
7. Cheng, J., Khin, K.T., Davis, M.E. Antitumor activity of ii-cyclodextrin polymer-campthothecin conjugates. Mol. Pharm., 2004, 1, 183-193.
8. Wall, M.E., Wani, M.C., Cook, C.E., Palmer, K.H., McPhail, A.T., Sims, G.A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 1966, 88, 3888-3890.
9. Muggia, F.M., Dimery, I., Arbuck, S.G. Camptothecin and its analogs. An overview of their potential in cancer therapeutics. Ann. N Y Acad. Sci., 1996, 803, 213-223.
10. Kehrer, D.F., Soepenberg, O., Loos, W.J., Verweij, J., Sparreboom, A. Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs, 2001, 12, 89-105.
11. Hertzberg, R.P., Caranfa, M.J., Hecht, S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 1989, 28, 4629-4638.
12. Mi, Z., Burke, T.G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry, 1994, 33, 10325-10336.
13. Burke, T.G., Mi, Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem., 1994, 37, 40-46.
14. Muggia, F.M., Creaven, P.J., Hansen, H.H., Cohen, M.H., Selawry, O.S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep., 1972, 56, 515-521.
15. Creaven, P.J., Allen, L.M., Muggia, F.M. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother. Rep., 1972, 56, 573-578.
16. Pommier, Y. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Curr. Med. Chem. Anticancer Agents, 2004, 4, 429-434.
17. Onnis, B., Rapisarda, A., Melillo, G. Development of HIF-1 inhibitors for cancer therapy. J. Cell Mol. Med., 2009, 13, 2780-2786.
18. Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C.A., Borgel, S.D., Carter, J.P., Hewitt, S.M., Shoemaker, R.H., Melillo, G. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res., 2004, 64, 6845-6848.
19. Schluep, T., Hwang, J., Hildebrandt, I.J., Czernin, J., Choi, C.H.J., Alabi, C.A., Mack, B.C., Davis, M.E. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc. Natl. Acad. Sci. USA, 2009, 106, 11394-11399.
20. Gabizon, A., Papahadjopoulos, D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta, 1992, 1103, 94-100.
21. Greenwald, R.B., Pendri, A., Conover, C.D., Lee, C., Choe, Y.H., Gilbert, C., Martinez, A., Xia, J., Wu, D., Hsue, M. Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorg. Med. Chem., 1998, 6, 551-562.
22. Numbenjapon, T., Wang, J., Colcher, D., Schluep, T., Davis, M.E., Duringer, J., Kretzner, L., Yen, Y., Forman, S.J., Raubitschek, A. Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin. Cancer Res., 2009, 15, 4365-4373.
23. Schluep, T., Cheng, J., Khin, K.T., Davis, M.E. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother. Pharmacol., 2006, 57, 654-6626.
24. Schluep, T., Hwang, J., Cheng, J., Heidel, J.D., Bartlett, D.W., Hollister, B., Davis, M.E. Preclinical efficacy of the camptothecinpolymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res., 2006, 12, 1606-1614.
25. Jensen, G., Hwang, J., Schluep, T. Antitumor activity of IT-101, a cyclodextrin-containing polymer-camptothecin nanoparticle, in combination with various anticancer agents in human ovarian cancer xenografts. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, 2008, p. 767.